At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 39 enrolled
Drug / intervention
LY3502970drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of 2 Different Formulations of LY3502970 in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3502970 for Healthy. Completed, enrolled 39 participants across 1 site.
Detailed Summary
The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedApr 2022
Enrollment StartMay 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedApr 22, 2022
Enrollment StartMay 17, 2022
Primary CompletionSep 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.2 years ago
Interventions
LY3502970drug
Administered orally.